New biomarkers help prolong the life expectancy of patients with lung neoplasia

meet the DNA through biomarkers of lung cancer, it would help make decisions in precision medicine more efficient and prolong the life expectancy of each person suffering from this neoplasm, a specialist highlighted this Thursday.

“Precision medicine has changed the treatment of lung cancer. Currently, patients are cared for according to the characteristics and particularities of the tumor, which gives better results, less toxicity, greater quality and life expectancy,” oncologist Maritza Ramos said at a press conference.

Ramos pointed out that biomarkers or molecular genetic tests are innovative parameters that allow the identification of mutated cancer genes, the classification of the tumor, as well as the phase in which it is found.

LOOK: Patient associations will launch “Oncological Traffic Light” on the National Cancer Law

Biomarker tests are a way to identify genes, proteins, and other substances (called biomarkers or biological markers) that provide information about cancer.

“With biomarkers we can reduce care costs and toxicity complications from therapies such as chemotherapy by personalizing patient care,” he said.

He asserted that in lung cancer there are about 14 biomarkers that can give a specific treatment.

To this end, today there is a Single Platform for Oncological Testing (PLUTON) in Mexico, which fIt was created to reduce waiting times between health professionals and patientssince the doctor will be able to quickly request tests, centralizing the information and generating statistics.

This platform has the Advanced Tumor Biobank and the largest cancer Big Data set in Latin America, which houses 70,000 samples of tumors and biomarkers, which are also used for the discovery and development of new drugs.

In addition to this, the platform offers education and training to oncologists, pathologists, surgeons and professionals from the pharmaceutical industry focused on lung cancer.

Leave a Reply